It isn’t entirely clear why the efficacy ... least two years. Pfizer executives, meanwhile, pledged to increase their shot’s market share during a January investor call. Moderna has said ...

according to Pfizer. Administering a third dose restores protective efficacy back up to 95% or more, it said. Meanwhile, Moderna also reported new data with its mRNA-1273 jab – which won't be ...

The company will compete in a market where GSK and Pfizer already have a presence. Earlier this month, Moderna released data ... to compare the safety and efficacy of its RSV shot with others ...

Moderna and Pfizer have both said that updated versions ... led to concerns that the current generation of shots may lack efficacy. It's encouraging, then, that Moderna's mRNA-1273.715 vaccine ...

Moderna Inc. MRNA edged up 0.58%, while Pfizer Inc. PFE gained 2.95% amid heightened focus on potential bird flu preparedness. CDC official John Nkengasong‘s Sunday memo, viewed by The ...

The stellar efficacy and safety profile of ... by other innovative vaccines (GSK's Shingrix, Pfizer's Prevnar) launched in recent years. Moderna's platform technology allows new genetic sequences ...